marijuana stock news

SOL Global Investments Announces Date Change For Their Conference Call To Discuss Fiscal 2019 Results And Corporate Updates to August 8th, 2019 at 4:00PM ET

Brady Cobb , Chief Executive Officer, will host the call starting at 4:00 p.m. Eastern Time . A question and answer session will immediately follow an initial presentation on SOL Global’s fiscal 2019 financial results and a corporate update. Additional participants from SOL Global will include Andy DeFrancesco , Chief Investment Officer and Chairman, Peter Liabotis , Chief Financial Officer and Paul Norman , Chief Executive Officer of SOL Global portfolio company HeavenlyRx.

Dial-in Information:

U.S. Dial-in Number: (646) 982-0366
U.S. Toll-Free Number: (866) 793-5054
International Access: uberconference.com/amwpr

About SOL Global Investments Corp.

SOL Global is an international investment company with a focus on, but not limited to, cannabis and cannabis related companies in legal U.S. states, the hemp and CBD marketplaces and the emerging European cannabis and hemp marketplaces. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami . It is this comprehensive approach that is positioning SOL Global as a future frontrunner in the United States’ medical cannabis industry.

SOURCE SOL Global Investments Corp.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Neptune Wellness Solutions Inc. (NEPT) Launches Forest Remedies Plant-Based Omega 3-6-9 Supplements

Neptune Launches Forest Remedies Plant-Based Omega 3-6-9 Supplements Neptune Wellness Solutions Inc.…

$EAPH Provides Update on Its Medicated Markets Partnership

Easton Pharmaceuticals Provides Update on Its Medicated Markets Partnership, Joint Initiatives and…

$OXIS Discusses Its Immunotherapeutic Development Strategy

Oxis Biotech Discusses Its Immunotherapeutic Development Strategy TAMPA, Fla., April 1, 2015…